Memantine Therapy in Amyotrophic Lateral Sclerosis
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic
lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of
increased neuronal death from any disease process. It is been shown that Memantine can
inhibit and reverse the abnormal hyperphosphorylation of Tau and therefore the investigators
are looking at the efficacy of Memantine at 10 mg twice a day (BID) to see if disease
progression correlates with possible changes in Tau in ALS patients based on ALS Functional
Rating Scale (ALSFRS) scores.